These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Reviewing current and emerging antiemetics for chemotherapy-induced nausea and vomiting prophylaxis. Natale JJ Hosp Pract (1995); 2015; 43(4):226-34. PubMed ID: 26308912 [TBL] [Abstract][Full Text] [Related]
6. A review of granisetron, 5-hydroxytryptamine3 receptor antagonists, and other antiemetics. Hsu ES Am J Ther; 2010; 17(5):476-86. PubMed ID: 20844345 [TBL] [Abstract][Full Text] [Related]
7. [ECCO 2005. Advances in the prevention of chemotherapy-induced nausea and vomiting]. Longo F; Mansueto G; Magnolfi E Tumori; 2006; 92(1):suppl 24-31. PubMed ID: 16683393 [No Abstract] [Full Text] [Related]
9. Aprepitant (EMEND): the role of substance P in nausea and vomiting. Prommer E J Pain Palliat Care Pharmacother; 2005; 19(3):31-9. PubMed ID: 16219609 [TBL] [Abstract][Full Text] [Related]
10. Rolapitant hydrochloride: prophylactic treatment for chemotherapy-induced nausea and vomiting. Navari R Drugs Today (Barc); 2016 Aug; 52(8):431-438. PubMed ID: 27722211 [TBL] [Abstract][Full Text] [Related]
11. Pathogenesis-based treatment of chemotherapy-induced nausea and vomiting--two new agents. Navari RM J Support Oncol; 2003; 1(2):89-103. PubMed ID: 15352652 [TBL] [Abstract][Full Text] [Related]
12. Antiemetics for cancer chemotherapy-induced nausea and vomiting. A review of agents in development. Rizk AN; Hesketh PJ Drugs R D; 1999 Oct; 2(4):229-35. PubMed ID: 10659396 [TBL] [Abstract][Full Text] [Related]
13. Update on the management of chemotherapy-related nausea and vomiting: an emphasis on the new class of agents--neurokinin-1 receptor antagonists. Gralla R Clin Adv Hematol Oncol; 2006 Jul; 4(7):507-8. PubMed ID: 17147235 [No Abstract] [Full Text] [Related]
14. The safety of antiemetic medications for the prevention of chemotherapy-induced nausea and vomiting. Navari RM Expert Opin Drug Saf; 2016; 15(3):343-56. PubMed ID: 26699406 [TBL] [Abstract][Full Text] [Related]
15. Fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting. Ruhlmann CH; Herrstedt J Expert Rev Anticancer Ther; 2012 Feb; 12(2):139-50. PubMed ID: 22316362 [TBL] [Abstract][Full Text] [Related]
16. Chemotherapy-induced nausea and vomiting: which antiemetic for which therapy? Schwartzberg LS Oncology (Williston Park); 2007 Jul; 21(8):946-53; discussion 954, 959, 962 passim. PubMed ID: 17715696 [TBL] [Abstract][Full Text] [Related]
17. [Croatian guideliness for prevention of chemotherapy induced nausea and vomiting]. Tomek R; Vrdoljak E; Vrbanec D; Nemet D; Matković V; Plestina S; Gugić D; Dintinjana RD; Bolanca A; Samarzija M; Petković M Lijec Vjesn; 2009; 131(3-4):49-53. PubMed ID: 19514248 [TBL] [Abstract][Full Text] [Related]
18. Rolapitant for the prevention of delayed nausea and vomiting over initial and repeat courses of emetogenic chemotherapy. Rapoport B; van Eeden R; Smit T Expert Rev Clin Pharmacol; 2017 Jan; 10(1):17-29. PubMed ID: 27894202 [TBL] [Abstract][Full Text] [Related]
19. Recent developments in the clinical pharmacology of rolapitant: subanalyses in specific populations. Rapoport BL; Aapro M; Chasen MR; Jordan K; Navari RM; Schnadig I; Schwartzberg L Drug Des Devel Ther; 2017; 11():2621-2629. PubMed ID: 28919712 [TBL] [Abstract][Full Text] [Related]
20. Risk-benefit of antiemetics in prevention and treatment of chemotherapy-induced nausea and vomiting. Herrstedt J Expert Opin Drug Saf; 2004 May; 3(3):231-48. PubMed ID: 15155151 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]